FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> FDA | Drug Trials | orphan drug status | Vical

Vical wins orphan drug status

The FDA has granted orphan drug status to Vical's vaccine for the herpes virus cytomegalovirus. A mid-stage trial is planned for the second part of the year among bone marrow donors and recipients. The virus occurs in about 30 percent to 60 percent of bone marrow and solid organ transplant patients.

- read this article from the AP for more


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about FDA   Drug Trials   orphan drug status   Vical